Contribute Try STAT+ Today

WASHINGTON — Congressional progressives secured a series of changes to the sweeping drug pricing bill the House is considering this week in return for dropping a threat to upend the vote altogether.

The changes do not significantly change Speaker Nancy Pelosi’s reforms, which would let Medicare negotiate the prices of certain high-cost drugs. Their tweaks include a slight increase in the number of drugs that would be negotiated each year, from 35 to 50, and a provision that will pave the path, but not explicitly enact, another policy meant to block drug makers from hiking their prices more than inflation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Mr. Floriko, are you trying to say that the Progressive Caucus is ineffectual and weak? That’s certainly what your “reporting” tells me. As it isn’t true (look back 4 years and compare the drift of the Democratic Party–despite Speaker Pelosi’s efforts to placate her donors), I’m curious to know who pressured you to write such a tendentious “report.” I realize you won’t answer. But I think you should know that many people read STAT who were born and raised in an era–not so long ago–in which respectable journalism aimed to convey information rather than manipulate readers. Some of us wonder what STAT’s relationship to the pharmaceutical industry is.

Comments are closed.